Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Researchers at Linköping University in Sweden made an unexpected discovery while investigating genetically unique women.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Why does Seal have scars? The singer's facial scars and bumps are caused by a skin condition. Learn what happened to his face ...